"10.1371_journal.pone.0064443","plos one","2013-05-16T00:00:00Z","Cristiana C Garcia; Wynne Weston-Davies; Remo C Russo; Luciana P Tavares; Milene A Rachid; José C Alves-Filho; Alexandre V Machado; Bernhard Ryffel; Miles A Nunn; Mauro M Teixeira","Laboratório de Imunofarmacologia, Departamento de Bioquímica e Imunologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Varleigh Ltd, London, United Kingdom; Departamento de Fisiologia e Biofísica, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Departamento de Patologia Geral, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil; Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil; CNRS UMR7355, CNRS and University Orleans, France and IIDMM, University of Cape Town, Cape Town, South Africa; Centre for Ecology and Hydrology, Wallingford, United Kingdom","Conceived and designed the experiments: CCG WW RCR BR MN MMT. Performed the experiments: CCG RCR LPT MAR AVM JCAF. Analyzed the data: CCG RCR LPT MAR. Contributed reagents/materials/analysis tools: WW AVM MN BR JCAF. Wrote the paper: CCG WW MN MMT.","The authors have the following interests. The author Dr. Wynne Weston-Davies is the Medical Director of Varleigh Ltd, the company that developed and supplied the C5a inhibitor, OmCI or coversin, used in this study. Co-authors Jose Carlos Alves-Filho and Bernhard Ryffel are PLOS ONE Editorial Board members. There are no further patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","05","Cristiana C Garcia","CCG",10,TRUE,6,6,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
